UnknownPhase 3NCT04145258
Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous Meningitis
Studying OBSOLETE: Tuberculous meningitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ANRS, Emerging Infectious Diseases
- Principal Investigator
- Fabrice Bonnet, M.D., Ph.D.University Hospital, Bordeaux
- Intervention
- Aspirin(drug)
- Enrollment
- 768 enrolled
- Eligibility
- 15 years · All sexes
- Timeline
- 2021 – 2026
Study locations (13)
- Cocody University Hospital, Abidjan, Côte d’Ivoire
- Treichville University Hospital, Abidjan, Côte d’Ivoire
- Yopougon University Hospital, Abidjan, Côte d’Ivoire
- University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar
- University Hospital Tambohobe, Fianarantsoa, Madagascar
- Morafeno University Hospital, Toamasina, Madagascar
- Kayelitsha District Hospital, Cape Town, South Africa
- Mitchells Plain Hospital, Cape Town, South Africa
- New Somerset Hospital, Cape Town, South Africa
- Dora Nginza Hospital, Port Elizabeth, South Africa
- Livingstone and PE Central Hospitals, Port Elizabeth, South Africa
- Mbarara Regional Reference Hospital, Mbarara, Uganda
- Regional Reference Hospital of Kabale, Mbarara, Uganda
Collaborators
European Union · European and Developing Countries Clinical Trials Partnership (EDCTP)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04145258 on ClinicalTrials.govOther trials for OBSOLETE: Tuberculous meningitis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT05383742Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous MeningitisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGPHASE2NCT05590455Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitisANRS, Emerging Infectious Diseases